134 related articles for article (PubMed ID: 34928100)
1. Co-Delivery of Paclitaxel and shMCL-1 by Folic Acid-Modified Nonviral Vector to Overcome Cancer Chemotherapy Resistance.
Nie W; Wang B; Mi X; Chen J; Yu T; Miao J; Lin Y; Yang T; Ran M; Hong Z; Liu X; Liang X; Qian Z; Gao X
Small Methods; 2021 May; 5(5):e2001132. PubMed ID: 34928100
[TBL] [Abstract][Full Text] [Related]
2. Co-delivery of paclitaxel (PTX) and docosahexaenoic acid (DHA) by targeting lipid nanoemulsions for cancer therapy.
Li B; Tan T; Chu W; Zhang Y; Ye Y; Wang S; Qin Y; Tang J; Cao X
Drug Deliv; 2022 Dec; 29(1):75-88. PubMed ID: 34964421
[TBL] [Abstract][Full Text] [Related]
3. Folic acid-coupled nano-paclitaxel liposome reverses drug resistance in SKOV3/TAX ovarian cancer cells.
Tong L; Chen W; Wu J; Li H
Anticancer Drugs; 2014 Mar; 25(3):244-54. PubMed ID: 24275314
[TBL] [Abstract][Full Text] [Related]
4. Tongguanteng injection reverses paclitaxel resistance via upregulation of TAB1 expression in ovarian cancer in vitro and in vivo.
Kong QW; Yang J; Li D; Ding YW; Hu YJ; Xue XC; Shi MZ; Jiang B; Zhou YY; Zhang M; Hu JD; Guo C; Chen JJ; Han YL
J Ethnopharmacol; 2023 Jan; 300():115728. PubMed ID: 36126783
[TBL] [Abstract][Full Text] [Related]
5. Multi-small molecule conjugations as new targeted delivery carriers for tumor therapy.
Shan L; Liu M; Wu C; Zhao L; Li S; Xu L; Cao W; Gao G; Gu Y
Int J Nanomedicine; 2015; 10():5571-91. PubMed ID: 26366078
[TBL] [Abstract][Full Text] [Related]
6. A novel targeted co-delivery nanosystem for enhanced ovarian cancer treatment via multidrug resistance reversion and mTOR-mediated signaling pathway.
Wang X; Xiong T; Cui M; Li N; Li Q; Zhu L; Duan S; Wang Y; Guo Y
J Nanobiotechnology; 2021 Dec; 19(1):444. PubMed ID: 34949180
[TBL] [Abstract][Full Text] [Related]
7. Targeted inhibition of phosphatidyl inositol-3-kinase p110β, but not p110α, enhances apoptosis and sensitivity to paclitaxel in chemoresistant ovarian cancers.
Jeong JY; Kim KS; Moon JS; Song JA; Choi SH; Kim KI; Kim TH; An HJ
Apoptosis; 2013 Apr; 18(4):509-20. PubMed ID: 23371322
[TBL] [Abstract][Full Text] [Related]
8. Folate and CD44 receptors dual-targeting hydrophobized hyaluronic acid paclitaxel-loaded polymeric micelles for overcoming multidrug resistance and improving tumor distribution.
Liu Y; Sun J; Lian H; Cao W; Wang Y; He Z
J Pharm Sci; 2014 May; 103(5):1538-47. PubMed ID: 24619562
[TBL] [Abstract][Full Text] [Related]
9. Folic Acid-Modified Nanoerythrocyte for Codelivery of Paclitaxel and Tariquidar to Overcome Breast Cancer Multidrug Resistance.
Zhong P; Chen X; Guo R; Chen X; Chen Z; Wei C; Li Y; Wang W; Zhou Y; Qin L
Mol Pharm; 2020 Apr; 17(4):1114-1126. PubMed ID: 32176509
[TBL] [Abstract][Full Text] [Related]
10. Difunctional Pluronic copolymer micelles for paclitaxel delivery: synergistic effect of folate-mediated targeting and Pluronic-mediated overcoming multidrug resistance in tumor cell lines.
Wang Y; Yu L; Han L; Sha X; Fang X
Int J Pharm; 2007 Jun; 337(1-2):63-73. PubMed ID: 17289311
[TBL] [Abstract][Full Text] [Related]
11. Nanomedicine-based paclitaxel induced apoptotic signaling pathways in A562 leukemia cancer cells.
Wang Y; Zhou L; Xiao M; Sun ZL; Zhang CY
Colloids Surf B Biointerfaces; 2017 Jan; 149():16-22. PubMed ID: 27716527
[TBL] [Abstract][Full Text] [Related]
12. Folic Acid and Poly(ethylene glycol) Decorated Paclitaxel Nanocrystals Exhibit Enhanced Stability and Breast Cancer-Targeting Capability.
Zhao J; Du J; Wang J; An N; Zhou K; Hu X; Dong Z; Liu Y
ACS Appl Mater Interfaces; 2021 Mar; 13(12):14577-14586. PubMed ID: 33728919
[TBL] [Abstract][Full Text] [Related]
13. Folic acid modified lipid-bilayer coated mesoporous silica nanoparticles co-loading paclitaxel and tanshinone IIA for the treatment of acute promyelocytic leukemia.
Li Z; Zhang Y; Zhu C; Guo T; Xia Q; Hou X; Liu W; Feng N
Int J Pharm; 2020 Aug; 586():119576. PubMed ID: 32603839
[TBL] [Abstract][Full Text] [Related]
14. Novel Water-Borne Polyurethane Nanomicelles for Cancer Chemotherapy: Higher Efficiency of Folate Receptors Than TRAIL Receptors in a Cancerous Balb/C Mouse Model.
Ajorlou E; Khosroushahi AY; Yeganeh H
Pharm Res; 2016 Jun; 33(6):1426-39. PubMed ID: 26908046
[TBL] [Abstract][Full Text] [Related]
15. CD44-Targeting PLGA Nanoparticles Incorporating Paclitaxel and FAK siRNA Overcome Chemoresistance in Epithelial Ovarian Cancer.
Byeon Y; Lee JW; Choi WS; Won JE; Kim GH; Kim MG; Wi TI; Lee JM; Kang TH; Jung ID; Cho YJ; Ahn HJ; Shin BC; Lee YJ; Sood AK; Han HD; Park YM
Cancer Res; 2018 Nov; 78(21):6247-6256. PubMed ID: 30115698
[TBL] [Abstract][Full Text] [Related]
16. Tumor-targeting and pH-sensitive lipoprotein-mimic nanocarrier for targeted intracellular delivery of paclitaxel.
Chen C; Hu H; Qiao M; Zhao X; Wang Y; Chen K; Guo X; Chen D
Int J Pharm; 2015 Mar; 480(1-2):116-27. PubMed ID: 25615984
[TBL] [Abstract][Full Text] [Related]
17. Delivery of baicalein and paclitaxel using self-assembled nanoparticles: synergistic antitumor effect in vitro and in vivo.
Wang W; Xi M; Duan X; Wang Y; Kong F
Int J Nanomedicine; 2015; 10():3737-50. PubMed ID: 26045664
[TBL] [Abstract][Full Text] [Related]
18. Reconstituted high density lipoprotein mediated targeted co-delivery of HZ08 and paclitaxel enhances the efficacy of paclitaxel in multidrug-resistant MCF-7 breast cancer cells.
Zhang F; Wang X; Xu X; Li M; Zhou J; Wang W
Eur J Pharm Sci; 2016 Sep; 92():11-21. PubMed ID: 27343697
[TBL] [Abstract][Full Text] [Related]
19. Targeting the Bcl-2 family and P-glycoprotein reverses paclitaxel resistance in human esophageal carcinoma cell line.
Shi X; Dou Y; Zhou K; Huo J; Yang T; Qin T; Liu W; Wang S; Yang D; Chang L; Wang C
Biomed Pharmacother; 2017 Jun; 90():897-905. PubMed ID: 28441715
[TBL] [Abstract][Full Text] [Related]
20. Anti-tumor activity of folate targeted biodegradable polymer-paclitaxel conjugate micelles on EMT-6 breast cancer model.
Wu D; Zheng Y; Hu X; Fan Z; Jing X
Mater Sci Eng C Mater Biol Appl; 2015 Aug; 53():68-75. PubMed ID: 26042692
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
